Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Simke W WaijerPriya VartDavid Z I CherneyGlenn M ChertowNiels JongsAnna Maria LangkildeJohannes F E MannOfri MosenzonJohn Joseph Valentine McMurrayEllen BurgessRicardo Correa-RotterBergur V StefanssonRobert D TotoDavid C WheelerHiddo J Lambers HeerspinkPublished in: Diabetologia (2022)
The study was funded by AstraZeneca.